Shivaani Kummar
Medical Oncology · Portland, ORNPI 1053612341
Payments from drug & device makers
Across 1,138 payments — averaging $6837.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$976K
- Otsuka Pharmaceutical Co., Ltd.$813K
- E.r. Squibb & Sons, L.L.C.$804K
- Deciphera Pharmaceuticals Inc.$797K
- Seagen Inc.$648K
- Modernatx, Inc.$586K
- plus $3.2M from 24 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $976,371 |
| Otsuka Pharmaceutical Co., Ltd. | 24 | $813,164 |
| E.r. Squibb & Sons, L.L.C. | 19 | $803,544 |
| Deciphera Pharmaceuticals Inc. | 156 | $796,615 |
| Seagen Inc. | 61 | $648,178 |
| Modernatx, Inc. | 105 | $585,996 |
| Day One Biopharmaceuticals | 348 | $543,993 |
| Taiho Oncology, Inc. | 4 | $488,894 |
| Incyte Corporation | 20 | $255,883 |
| Pfizer | 13 | $253,161 |
| Merck | 4 | $249,940 |
| ADC Therapeutics America, Inc. | 13 | $206,098 |
| Daiichi Sankyo Inc. | 68 | $174,024 |
| Amgen | 7 | $136,077 |
| Gilead | 7 | $135,570 |
| Springworks Therapeutics, Inc. | 38 | $113,758 |
| Mirati Therapeutics, Inc. | 25 | $92,226 |
| EMD Serono, Inc. | 134 | $91,638 |
| Dynavax Technologies Corporation | 17 | $85,380 |
| Astrazeneca UK Limited | 2 | $82,136 |
| Eli Lilly | 3 | $76,034 |
| Bayer | 32 | $71,411 |
| Hoffmann-la Roche Limited | 5 | $36,383 |
| Eisai Inc. | 8 | $28,906 |
| Ares Trading SA | 11 | $23,241 |
| Boehringer Ingelheim International GmbH | 4 | $8,581 |
| Illumina, Inc. | 1 | $2,084 |
| Boehringer Ingelheim | 1 | $1,140 |
| Aadi Bioscience, Inc. | 1 | $550 |
| Sandoz | 1 | $20 |
How this compares
$7,780,997 in reported general payments places this provider in the 90th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Portland
- Matthew TaylorPortland$25.1M
- Rachel SanbornPortland$17.2M
- Christopher RyanPortland$10.3M
- Brendan CurtiPortland$8.6M
- Zahi MitriPortland$8.5M
- Julie GraffPortland$8.5M
- Rom LeidnerPortland$5.5M
- Charles LopezPortland$5.3M
- David PagePortland$4M
- Jeremy CetnarPortland$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.